A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
The first patient has been dosed in HMNC and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study.
A new study from Northwestern Medicine has identified for the first time how ketamine works so quickly, and how it might be adapted for use as...
Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
Awakn Life Science’s study exploring the use of ketamine as a treatment for Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior is...
Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
Cybin Inc.
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
New research has suggested that sub-anaesthetic doses of ketamine could be beneficial for conditions such as post-traumatic stress disorder (PTSD), anxiety, addiction and eating disorders.
